Impact of sacubitril/valsartan on patient outcomes in heart failure: evidence to date

S Akbar, N Kabra, WS Aronow - Therapeutics and Clinical Risk …, 2020 - Taylor & Francis
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …
被引用次数：5 相关文章

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date

S Akbar, N Kabra, WS Aronow - 2020 - touroscholar.touro.edu
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …
[HTML] nih.gov

[HTML][HTML] Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date

S Akbar, N Kabra, WS Aronow - Therapeutics and Clinical Risk …, 2020 - ncbi.nlm.nih.gov
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date

S Akbar, N Kabra, WS Aronow - Therapeutics and Clinical …, 2020 - search.proquest.com
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date

S Akbar, N Kabra, WS Aronow - … and clinical risk …, 2020 - pubmed.ncbi.nlm.nih.gov
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date.

S Akbar, N Kabra, WS Aronow - Therapeutics & Clinical Risk …, 2020 - search.ebscohost.com
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date

S Akbar, N Kabra, WS Aronow - Therapeutics and Clinical Risk …, 2020 - hero.epa.gov
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date

S Akbar, N Kabra, WS Aronow - Therapeutics and Clinical Risk …, 2020 - dovepress.com
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date.

S Akbar, N Kabra, WS Aronow - Therapeutics and Clinical Risk …, 2020 - europepmc.org
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …